{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:53Z","timestamp":1789506713131,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128965","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:18:17Z","timestamp":1785071897000},"page":"128965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Qualification of a high-throughput luminescence-based Serum Bactericidal Activity assay to assess the functionality of human sera against five Shigella serotypes"],"prefix":"10.1016","volume":"88","author":[{"given":"Giuseppe","family":"Boccadifuoco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Verdirosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Lashchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Piu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Hogrefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Sunshine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Micoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Rhyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Alaimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Molesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Montomoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Manenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128965_bb0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0140-6736(17)33296-8","article-title":"Shigellosis","volume":"391","author":"Kotloff","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128965_bb0010","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the global burden of disease study 1990-2016","volume":"18","author":"Khalil","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128965_bb0015","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S1473-3099(18)30362-1","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Troeger","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128965_bb0020","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.00165-19","article-title":"In silico serotyping based on whole-genome sequencing improves the accuracy of Shigella identification","author":"Wu","year":"2019","journal-title":"Appl Environ Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128965_bb0025","doi-asserted-by":"crossref","DOI":"10.5001\/omj.2023.65","article-title":"Shigella flexneri serotypes: o-antigen structure, serotype conversion, and serotyping methods","volume":"38","author":"Sadredinamin","year":"2023","journal-title":"Oman Med J"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128965_bb0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12223-020-00773-w","article-title":"Shigella flexneri: an emerging pathogen","volume":"65","author":"Nisa","year":"2020","journal-title":"Folia Microbiol (Praha)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128965_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/21505594.2023.2280838","article-title":"Pathogenicity and virulence of Shigella sonnei: a highly drug-resistant pathogen of increasing prevalence","volume":"14","author":"Matanza","year":"2023","journal-title":"Virulence"},{"key":"10.1016\/j.vaccine.2026.128965_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO bacterial priority pathogens list 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","author":"Sati","year":"2025","journal-title":"Lancet Infect Dis."},{"issue":"11","key":"10.1016\/j.vaccine.2026.128965_bb0045","doi-asserted-by":"crossref","first-page":"e1819","DOI":"10.1016\/S2214-109X(23)00421-7","article-title":"Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries","volume":"11","author":"Giersing","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128965_bb0050","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/vaccines10091376","article-title":"The Shigella vaccines pipeline","volume":"10","author":"MacLennan","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128965_bb0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/jb.92.1.17-22.1966","article-title":"Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine","volume":"92","author":"Formal","year":"1966","journal-title":"J Bacteriol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128965_bb0060","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/157.5.1068","article-title":"Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population","volume":"157","author":"Cohen","year":"1988","journal-title":"J Infect Dis"},{"issue":"9046","key":"10.1016\/j.vaccine.2026.128965_bb0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128965_bb0070","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1080\/21645515.2019.1606971","article-title":"Serum IgG antibodies to Shigella lipopolysaccharide antigens \u2013 a correlate of protection against shigellosis","volume":"15","author":"Cohen","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128965_bb0075","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1\u20134-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128965_bb0080","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"<i>Shigella<\/i> isolates from the global enteric multicenter study inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128965_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035616","article-title":"High yield production process for Shigella outer membrane particles","volume":"7","author":"Berlanda Scorza","year":"2012","journal-title":"PloS One"},{"issue":"36","key":"10.1016\/j.vaccine.2026.128965_bb0090","doi-asserted-by":"crossref","first-page":"24922","DOI":"10.1074\/jbc.M114.566570","article-title":"Modulation of endotoxicity of <i>Shigella<\/i> generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants","volume":"289","author":"Rossi","year":"2014","journal-title":"J Biol Chem."},{"key":"10.1016\/j.vaccine.2026.128965_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101076","article-title":"Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: results from a phase 2b randomized, placebo-controlled challenge study in adults","volume":"39","author":"Frenck","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128965_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00725-8","article-title":"A next-generation GMMA-based vaccine candidate to fight shigellosis","volume":"8","author":"Rossi","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128965_bb0105","doi-asserted-by":"crossref","first-page":"e971","DOI":"10.1093\/infdis\/jiae273","article-title":"The Shigella project team, safety and immunogenicity of a 4-component generalized modules for membrane antigens Shigella vaccine in healthy European adults: randomized, phase 1\/2 study","volume":"230","author":"Leroux-Roels","year":"2024","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128965_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-025-01305-8","article-title":"Evaluation of cross-functional antibody responses elicited by a four-component GMMA Shigella vaccine","volume":"10","author":"Caradonna","year":"2025","journal-title":"NPJ Vaccines."},{"issue":"1","key":"10.1016\/j.vaccine.2026.128965_bb0115","first-page":"51","article-title":"Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli","volume":"26","author":"Ravenscroft","year":"2016","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2026.128965_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103310","article-title":"Human challenge study with a Shigella bioconjugate vaccine: analyses of clinical efficacy and correlate of protection","volume":"66","author":"Talaat","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2026.128965_bb0125","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/vaccines10020212","article-title":"The ongoing journey of a Shigella bioconjugate vaccine","volume":"10","author":"Martin","year":"2022","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128965_bb0130","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1073\/pnas.96.9.5194","article-title":"Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1","volume":"96","author":"Pozsgay","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.vaccine.2026.128965_bb0135","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1073\/pnas.0900891106","article-title":"Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates","volume":"106","author":"Robbins","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128965_bb0140","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128965_bb0145","article-title":"Safety and immunogenicity of a Shigella bivalent conjugate vaccine (ZF0901) in 3-month- to 5-year-old children in China","volume":"10","author":"Mo","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128965_bb0150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41541-024-00822-2","article-title":"Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. Sonnei investigational vaccine","volume":"9","author":"Conti","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128965_bb0155","series-title":"Vaccine adjuvants. Methods in molecular biology","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-60761-585-9_14","article-title":"Functional antibody assays","volume":"626","author":"Feavers","year":"2010"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128965_bb0160","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2026.128965_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1404637","article-title":"Current challenges and improvements in assessing the immunogenicity of bacterial vaccines","volume":"15","author":"Fantoni","year":"2024","journal-title":"Front Microbiol"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128965_bb0170","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128965_bb0175","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00412-16","article-title":"Functional and antigen-specific serum antibody levels as correlates of protection against Shigellosis in a controlled human challenge study","volume":"24","author":"Shimanovich","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2026.128965_bb0180","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00146-18","article-title":"Development, interlaboratory evaluations, and application of a simple, high-throughput Shigella serum bactericidal assay","volume":"3","author":"Nahm","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2026.128965_bb0185","article-title":"A high-throughput Shigella-specific bactericidal assay","volume":"144","author":"Weerts","year":"2019","journal-title":"J Vis Exp"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128965_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172163","article-title":"Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout","volume":"12","author":"Necchi","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128965_bb0195","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.05028-11","article-title":"Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis","volume":"18","author":"Mak","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128965_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ht9020014","article-title":"Intra-laboratory evaluation of luminescence based high-throughput serum bactericidal assay (L-SBA) to determine bactericidal activity of human sera against Shigella","volume":"9","author":"Rossi","year":"2020","journal-title":"High Throughput"},{"key":"10.1016\/j.vaccine.2026.128965_bb0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/biotech11030029","article-title":"Setup and characterization of a high-throughput luminescence-based serum bactericidal assay (L-SBA) to determine functionality of human sera against Shigella flexneri","volume":"11","author":"Mancini","year":"2022","journal-title":"BioTech"},{"key":"10.1016\/j.vaccine.2026.128965_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011123","article-title":"High-throughput luminescence-based serum bactericidal assay optimization and characterization to assess human sera functionality against multiple Shigella flexneri serotypes","volume":"25","author":"Caradonna","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128965_bb0220","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/21645515.2019.1640427","article-title":"Functional antibodies as immunological endpoints to evaluate protective immunity against Shigella","volume":"16","author":"Ndungo","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128965_bb0225","first-page":"970","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2026.128965_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127896","article-title":"Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines","volume":"68","author":"Rhyne","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128965_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003708","article-title":"The rising dominance of Shigella sonnei: an intercontinental shift in the etiology of bacillary dysentery","volume":"9","author":"Thompson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128965_bb0240","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1128\/IAI.68.10.6056-6061.2000","article-title":"Comparison of O-antigen gene clusters of Escherichia coli (Shigella) sonnei and Plesiomonas shigelloides O17: sonnei gained its current plasmid-borne O-antigen genes from P. Shigelloides in a recent event","volume":"68","author":"Shepherd","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2026.128965_bb0245","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s42003-025-08258-7","article-title":"The characterization of Klebsiella pneumoniae associated with neonatal sepsis in low- and middle-income countries to inform vaccine design","volume":"8","author":"Nonne","year":"2025","journal-title":"Commun Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:44:12Z","timestamp":1789505052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"alternative-id":["S0264410X26007747"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128965","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Qualification of a high-throughput luminescence-based Serum Bactericidal Activity assay to assess the functionality of human sera against five Shigella serotypes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128965"}}